How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and resource savings reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance consultation

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about ripretinib

Marketing authorisation indication

2.1

Ripretinib (Qinlock, Deciphera Pharmaceuticals) is indicated for 'the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib'.

Price

2.3

The list price of ripretinib is £18,400 per 30‑day supply (excluding VAT; company submission). This is based on a 150‑mg dose once daily (3 50‑mg tablets).

2.4

The company has a commercial arrangement, which would have applied if ripretinib had been recommended.

Carbon Reduction Plan

2.5

Information on the Carbon Reduction Plan for UK carbon emissions for Deciphera Pharmaceuticals will be included here when guidance is published.